ANI Pharmaceuticals Inc expected to post earnings of 95 cents a share - Earnings Preview

ANI Pharmaceuticals

02/08/2024 16:01

* ANI Pharmaceuticals Inc  ANIP.OQ   ANIP.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 6
for the period ending June 30 2024
    * The Baudette Minnesota-based  company is expected to
report a
10.7% increase in revenue to $129.054 million from $116.55
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for ANI Pharmaceuticals Inc
is for
earnings of 95 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ANI
Pharmaceuticals Inc is $81.00​, above​ its last closing price
of $63.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  1.00        1.00       1.21      Beat    21.5
 Jan. 1 2024               0.86       1.27      Beat    17
 Jan. 1 0001   0.85        0.84       1.27      Beat    50.6​
 Jan. 1 0001   0.67        0.68       1.28      Beat    88.9
 ​​Jan.        0.36        0.35       0.76      Beat    231.9
 1 0001                                                 
 Dec. 31 2022  0.66        0.67       0.76      Beat    13.1​
 Jan. 1 0001   0.55        0.22       0.64      Beat    15.8
 Jan. 1 0001   0.22        0.22       0.13      Missed  -40.9
 This summary was machine generated August 2 at 15:00 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)